On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics

Basit Öğe Kaydı
dc.authoridBozkurt, ibrahim halil/0000-0003-1268-5636
dc.contributor.authorBozkurt, Ibrahim Halil
dc.contributor.authorSefik, Ertugrul
dc.contributor.authorCelik, Serdar
dc.contributor.authorYesilova, Arda
dc.contributor.authorKoras, Omer
dc.contributor.authorDegirmenci, Tansu
dc.date.accessioned2024-09-18T20:53:02Z
dc.date.available2024-09-18T20:53:02Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractIntroduction and hypothesis We aimed to compare on-demand and continuous use of fesoterodine 4 mg concerning efficacy and adverse effects. Methods A total of 100 patients who were diagnosed with non-neurogenic overactive bladder (OAB) syndrome were included in the study. All patients were evaluated with MMSE, ICIQ-SF, SEAPI quality of health and OAB-V8 questionnaires, at the beginning, 1st month and 4th month. Fesoterodine 4 mg was started for treatment. At the end of the 1st month, patients who obtained benefit from the treatment were 1:1 randomized into two groups. In group 1, fesoterodine 4 mg was given 1 x 1 in a standard manner whereas in group 2 patients took the pills on demand. Both groups were evaluated for efficacy and adverse events at 4 months. Results Final analyses included 69 patients. At 4-month follow-up, OAB-V8 scores were significantly improved compared to 1 month in both groups. Again at h months, no difference was detected between the two groups for MMSE, ICIQ-SF and SEAPI scores. In continuous usage group, 4th month MMSE scores were significantly lower than 1st month scores. At 4 months, dry mouth and constipation were lower in the on-demand group compared to continuous usage group. Conclusions Compared to standard continuous usage, on-demand usage of fesoterodine showed similar efficacy with fewer adverse events.en_US
dc.identifier.doi10.1007/s00192-022-05250-1
dc.identifier.endpage2132en_US
dc.identifier.issn0937-3462
dc.identifier.issn1433-3023
dc.identifier.issue8en_US
dc.identifier.pmid35666289en_US
dc.identifier.scopus2-s2.0-85131435242en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2127en_US
dc.identifier.urihttps://doi.org/10.1007/s00192-022-05250-1
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11544
dc.identifier.volume33en_US
dc.identifier.wosWOS:000806672200001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofInternational Urogynecology Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOveractive bladderen_US
dc.subjectFesoterodineen_US
dc.subjectOn-demand therapyen_US
dc.subjectContinuous useen_US
dc.subjectAntimuscarinicsen_US
dc.titleOn-demand use of fesoterodine: a new paradigm for extended release antimuscarinicsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
776.59 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu